Amsterdam Molecular Therapeutics (AMT) (RHP.DE) Holding N.V. (in liquidation) Announces Publication of its Accounts for 2011 and Notice of Annual General Meeting
7/16/2012 10:04:24 AM
More...
|
Amsterdam Molecular Therapeutics (AMT) (RHP.DE) Receives Further Opinion on Glybera® Marketing Authorization Application
4/23/2012 7:04:47 AM
More...
|
Amsterdam Molecular Therapeutics (AMT) (RHP.DE) Announces Completion of Disposal of its Operations to uniQure B.V. and its Dissolution Becoming Effective
4/6/2012 10:01:17 AM
More...
|
Amsterdam Molecular Therapeutics (AMT) (RHP.DE) Announces Results of Extraordinary General Meeting
4/2/2012 10:27:37 AM
More...
|
Amsterdam Molecular Therapeutics (AMT) (RHP.DE) Publishes Positive Data from Glybera® 14 Week Study
3/28/2012 7:21:04 AM
More...
|
Amsterdam Molecular Therapeutics (AMT) (RHP.DE) Receives Request for Further Information From CHMP on Glybera(R)
2/21/2012 10:10:24 AM
More...
|
Amsterdam Molecular Therapeutics (AMT) (RHP.DE) Announces European Commission (EC) Delays Decision on Glybera® Marketing Authorisation and Requests Further Information From the CHMP
1/30/2012 7:05:45 AM
More...
|
Amsterdam Molecular Therapeutics (AMT) (RHP.DE) Receives US Orphan Designation for Hemophilia B Gene Therapy
1/4/2012 9:59:37 AM
More...
|
Amsterdam Molecular Therapeutics (AMT) (RHP.DE) Announces € 2.5 Million Equity Raise
1/3/2012 9:05:31 AM
More...
|
Amsterdam Molecular Therapeutics (AMT) (RHP.DE) Announces Negative Equity Position
12/15/2011 10:42:30 AM
More...
|
|